ライフサイエンスコーパス: DES

1 DES for percutaneous coronary intervention appears to be

2 DES may warrant improved efficacy irrespective of stent

3 DES outcomes in the Liberal era were significantly bette

4 DES showed a good solubility of phenolic compounds with

5 DES use varied, from 56% in the Transitional era to 85%

6 DES, compared with BMS, were associated with a significa

7 DESs are green solvents characterized by high availabili

8 DESs have been first explored as electrolytic and enviro

9 analysis by dividing the study period into 3 DES eras: Transitional (April 23, 2003, to June 30, 2004

10 ational Patient Register, we evaluated 4,303 DES-PCI-treated patients with a surgical procedure and c

11 A total of 537 patients (n=153 BRS; n=384 DES) were included.

12 Images were acquired in 61 patients (42 DES and 19 BMS) presenting with definite VLST.

13 s and, therefore, to help in the design of a DES for a specific reaction and sample.

14 crown of filter paper, soaked in a RTIL or a DES, placed upon a disposable screen printed carbon cell

15 amolecular structure of XoCH, but CiCH is a "DES-in-water" solution.

16 ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-E

17 ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-E

18 METHODS AND ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-E

19 Among 8582 subjects in ADAPT-DES, 405 (4.7%) had SVG PCI.

20 bjects in the prospective, multicenter ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With

21 lar observational studies (PROMETHEUS, ADAPT-DES [the Assessment of Dual AntiPlatelet Therapy with Dr

22 ternal validation was performed in the ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-E

23 compared 8448 patients enrolled in the ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With

24 aneous coronary intervention with additional DES, atheroablative therapies by laser or mechanical ath

25 ncreased mortality with prolonged DAPT after DES implantation.

26 as only present within the first month after DES-PCI, suggesting that surgery might be undertaken ear

27 nts requiring surgery within 12 months after DES-PCI had an increased risk of MI and cardiac death co

28 Less minor amputations occurred after DES until 6 months post-treatment (P=0.03).

29 the minimum duration of DAPT required after DES implantation?

30 = 40) received kidney transplantation after DES with IVIG + rituximab +/- PLEX (plasma exchange) +/-

31 hed cohort, no significant association among DES (vs BMS) use and outcomes was observed at 1 and 2 ye

32 ts with 239 lesions received BVS (n=112) and DES (n=127).

33 choline chloride/p-toluenesulfonic acid and DES choline chloride/p-toluenesulfonic acid-water in the

34 ces in target-vessel failure between BRS and DES (4.6% versus 7.7%; P=0.21).

35 l no significant differences between BRS and DES (hazard ratio, 1.54; 95% confidence interval, 0.69-3

36 was achieved in 99.3% and 96.6% of BRS- and DES-treated patients, respectively (P=0.07).

37 ry restenosis was comparable between BVS and DES (7.8% versus 8.9%; P=0.90).

38 duals receiving multilesion PCI with BVS and DES and follow-up angiography at 6 to 8 months were stud

39 s the intraindividual performance of BVS and DES in patients receiving multilesion PCI and follow-up

40 1.6%; P=0.48) did not differ between BVS and DES.

41 ith 3-vessel or left main CAD, both CABG and DES-PCI were associated with substantial and sustained q

42 efficacy of EES in bare-metal stent ISR and DES-ISR.

43 (GLA, TTR, PRKAG2, LAMP2, PTPN11, RAF1, and DES).

44 cture is disrupted; instead, water-water and DES-water interactions dominate.

45 border zone markers including NPPB, ANKRD1, DES, UCHL1, JUN, and FOXP1.

46 ion was performed and choline chloride-based DES containing oxalic acid as a hydrogen bond donor with

47 Choline chloride:phenol-based DES showed the best results.

48 A alcohol-based-DES consists of betaine hydrochloride - glycerol (1:3) a

49 GCH and a high ratio of beta-glucose in both DESs.

50 isk was defined by a prior MI rather than by DES implantation, the primary analysis provides moderate

51 In CL-DES-MNF-AALLME, the extraction solvent is novel magnetic

52 r-agitated liquid-liquid microextraction (CL-DES-MNF-AALLME) coupled with ETAAS was proposed for simu

53 The potential of the CL-DES-MNF-AALLME was considered in walnut, rice, tomato pa

54 ed, patient-blinded, randomized, comparative DES trial that enrolled patients from June 18, 2008, to

55 The authors sought to compare DES versus DCB for femoropopliteal lesions through 36 mo

56 oronary intervention, even with contemporary DES.

57 probability of treatment weighting to create DES- and BMS-treated groups whose observed baseline char

58 patients transplanted after desensitization (DES) who were DSA+ versus DSA- at transplant.

59 tion [CMR], 38 no rejection in desensitized [DES] and non-DES control groups) for reverse transcripti

60 Desmin (DES) mutations cause severe skeletal and cardiac muscle

61 le, cyclophosphamide and diethylstilbestrol (DES), for which both human and animal studies have demon

62 pionate (TP), estrogen - Diethystilbesterol (DES) and glucocorticoid - Dexamethasone (DEX)), only and

63 Currently, >30 different DES are commercially available in Europe, with fewer ava

64 Initially, screening of five different DES for proposed extraction was performed and choline ch

65 Five (E2, DES, DPN, BPAF, Coum, 1-BP) of 16 compounds tested by re

66 -bond network between the components of each DES was evaluated and the diffusion coefficients at 298.

67 on, randomly allocated to everolimus-eluting DES or to an equivalent BMS platform in the EXAMINATION

68 The curcumin concentration in enriched DES phase was analyzed by UV-Visible spectrophotometer.

69 Six-month patency rates were 48.0% for DES and 35.1% for PTA+/-BMS (P=0.096) in the modified-in

70 was significantly lower (range 3.2%-5.5% for DES patients and 1.1%-2.9% for normal subjects).

71 ates of primary patency were 79% and 80% for DES and DCB at 12 months (p = 0.96) but decreased to 54%

72 h those of 155 patients treated with EES for DES-ISR.

73 red in this study will contribute to further DES implementation in extraction of biologically active

74 -inferiority trials against early-generation DES and have typically shown similar efficacy and superi

75 However, the first-generation DES had substantial drawbacks, including delayed healing

76 randomly assigned to have a first-generation DES implanted.

77 received BMS, 15% received first-generation DES, and 47% received second-generation DES.

78 ccording to stent use: BMS, first-generation DES, and newer generation DES group.

79 ng bare-metal stents (BMS), first-generation DES, and newer generation DES in a large unselected nati

80 .68; P<0.001), but not with first-generation DES, compared with BMS-treated patients.

81 eneration DES, but not with first-generation DES, compared with the patients treated with BMS.

82 r DES platforms compared to first-generation DES.

83 How the safety profile of new-generation DES compares with that of bare-metal stents (BMS) is les

84 The performance of new-generation DES in the first year after implantation means that BMS

85 utcomes after implantation of new-generation DES or BMS among patients undergoing percutaneous corona

86 , first-generation DES, and newer generation DES group.

87 , first-generation DES, and newer generation DES in a large unselected national data set from the BCI

88 DAPT after implantation of newer-generation DES and in secondary prevention after MI.

89 DAPT after implantation of newer-generation DES entails a tradeoff between reductions in stent throm

90 who received predominantly newer-generation DES to answer: A1) Use of DAPT for 12 months, as compare

91 Subsequently, newer-generation DES were introduced with thinner struts, different scaff

92 g stent (DES) platforms, previous generation DES, and bare-metal stents (BMS) for percutaneous corona

93 r in patients treated with second-generation DES (odds ratio, 0.51; 95% confidence interval, 0.38-0.6

94 Patients receiving second-generation DES for the treatment SVG disease have lower rates of in

95 Implantation of BRS versus second-generation DES in chronic total occlusion was associated with simil

96 are efficacy and safety of second-generation DES over BMS in large coronary culprit ST-segment elevat

97 r in patients treated with second-generation DES, but not with first-generation DES, compared with th

98 tion DES, and 47% received second-generation DES.

99 ar safety and efficacy of 2 newer-generation DESs in randomized participants with non-ST-elevation ac

100 safety and efficacy of the newer-generation DESs used.

101 he determinations of D and k(0) in glyceline DES by voltammetric studies using the Nicholson approach

102 Hydrophobic DES was prepared by mixing amylalcohol as a hydrogen bon

103 antiproliferative drugs for achieving ideal DES performance.

104 Insulin is mixed with ILs/DES made from Choline and Geranic acid (CAGE) to form a

105 sis was frequently observed in BMS (40.5% in DES and 68.4% in BMS; P=0.056).

106 pansion were more frequently demonstrated in DES than in BMS patients, whereas neoatherosclerosis was

107 It covers recent developments in DES research, frames outstanding scientific questions, a

108 This sensor can detect gliadin in DES, with a dynamic range between 1 and 100 mug/L and an

109 frames with neoatherosclerosis was lower in DES than in BMS (15.56% [12.24-28.57] versus, 56.41% [40

110 erformed in 20% (w/v) aqueous glycerol or in DES (lactic acid: glucose) instead of water.

111 e risk of the primary outcome was reduced in DES recipients compared with BMS recipients (HR 0.84, 95

112 cutive lipid neointima length was shorter in DES than in BMS (2.4 [1.2-3.6] and 5.3 [3.0-7.0] mm; P=0

113 Surgery in DES-PCI-treated patients was associated with an increase

114 tomography imaging demonstrated that VLST in DES and BMS had a wide variety of abnormal findings, suc

115 thus a low-cost additive that forms gels in DESs from readily available constituents, with conductiv

116 Comparing RLi reactivities in DESs with those observed in pure glycerol or THF suggest

117 stent by percutaneous coronary intervention (DES-PCI).

118 b ischemia caused by infrapopliteal lesions, DES provide better 6-month patency rates and less amputa

119 t and intense with the BVS than the metallic DES and could be determined by patient baseline characte

120 (DES) based vortex assisted microextraction (DES-VAME) method for preconcentration of As and Sb from

121 solvent based liquid phase microextraction (DES-LPME) for trace determination by a slotted quartz tu

122 solvent-based liquid phase microextraction (DES-LPME).

123 stigated and optimized using fabricated MOF- DES/MIPs monolithic fiber.

124 olvents/molecularly imprinted polymers (MOF- DES/MIPs) and were used for microextraction of phthalate

125 Finally, the p.Glu401Asp mutated DES gene was transfected into cell lines and analyzed by

126 The final myco-DES (dried extract spots) protocol allows quantification

127 ities to electrolyte dissolved in the native DES.

128 8 no rejection in desensitized [DES] and non-DES control groups) for reverse transcription into cDNA,

129 To determine if non-DES/non-MGD Asian meibum was significantly different fro

130 ps (P < 0.01 vs DES control, P < 0.05 vs non-DES control).

131 We identified the novel DES mutation p.Glu401Asp in a large Spanish family with

132 scribe clinically and functionally the novel DES-p.Glu401Asp mutation as a cause of inherited left ve

133 cessary in 14% of DCB patients versus 17% of DES patients (p = 0.50).

134 observed in 22% of DCB-treated versus 21% of DES-treated patients (p = 0.90).

135 er 31, 2010, and examined the association of DES versus BMS with 1-year outcomes: death; death or MI;

136 ed the long-term quality-of-life benefits of DES-PCI versus CABG for patients with 3-vessel or left m

137 The spectrophotometric characteristics of DES extracts of 65 EVOO samples were related to the tota

138 Different combinations of DES consisting of choline chloride (ChCl) in various mix

139 vent is novel magnetic nanofluid consists of DES based magnetic multiwall carbon nanotubes which can

140 Further development of DES technology should target improvements in clinical ou

141 le shows a systematic study of the impact of DES choline chloride/p-toluenesulfonic acid and DES chol

142 The impact of DES versus BMS implantation was consistent irrespective

143 The presentation of DES-ISR is not benign and is challenging for optimal tre

144 vity patterns that can ensure propagation of DES-induced neural excitation, potentially making it pos

145 ffect of parameters such as pH, mol ratio of DES composition, volume of DES, volume of tetrahydrofura

146 ggest comparable effectiveness and safety of DES versus DCB plus bailout stenting in femoropopliteal

147 is best described as an aqueous solution of DES components.

148 mechanism guides individualized treatment of DES-ISR to improve clinical outcomes.

149 intracoronary imaging, for the treatment of DES-ISR, is recommended based on the specific cause of r

150 ng the extraction such as type and volume of DES and emulsifier, pH and ionic strength, were optimise

151 pH, mol ratio of DES composition, volume of DES, volume of tetrahydrofuran (THF) and sample volume w

152 to provide information on the structures of DESs, the kinetics and thermodynamics properties, the in

153 amework needed for a deeper understanding of DESs.

154 ed the challenges associated with the use of DESs during the DLLME techniques.

155 mproved upon by 67 folds using the optimized DES-LPME-SQT-FAAS method.

156 ions were randomized to receive PTA+/-BMS or DES with paclitaxel.

157 3-vessel or left main CAD to either CABG or DES-PCI.

158 vention were randomly assigned 1:1 to DCB or DES after successful target lesion pre-dilation.

159 ct between the paper crown soaked in RTIL or DES and SPCE electrodes is assured by a gasket, and all

160 upporting material such as paper of RTILs or DESs which are characterized by profitable electrical co

161 very and enrichment factor compared to other DESs.

162 kidney transplant recipients undergoing PCI, DES was associated with better clinical outcomes beyond

163 y intervention with drug-eluting stents (PCI-DES) in reducing the rate of major adverse cardiovascula

164 tality rate was 23.7% (99 deaths) in the PCI-DES group and 18.7% (72 deaths) in the CABG group (hazar

165 ity rate was significantly higher in the PCI-DES group than in the CABG group (24.3% [159 deaths] vs.

166 s to lower all-cause mortality than with PCI-DES in long-term follow-up.

167 Some experimental variables such as pH, DES solvent type and volume, aprotic solvent type and vo

168 pose a differential expansion sandwich plus (DES+) revision to the original TBM model for cerebral co

169 ll persists with newer biodegradable polymer DES generations against second-generation permanent poly

170 h the early generation biodegradable polymer DES platforms compared to first-generation DES.

171 A variety of biodegradable polymer DES platforms have been clinically tested, showing equal

172 ted with polymer-free versus durable polymer DES.

173 is done with polymer-free or durable polymer DES.

174 against second-generation permanent polymer DES needs to be explored.

175 s with the standard-bearer permanent polymer DES within the first year of implantation.

176 enge (P = 0.0007) observed, whereas prenatal DES or DEX treatment had no effects upon insulin secreti

177 al disease were randomly assigned to primary DES implantation or DCB angioplasty with bailout stentin

178 ecember 2010; 2400 and 845 patients received DES and BMS, respectively.

179 y and correlates of ST in patients receiving DES, specifically examining the impact of risk factors m

180 Recently, DES mutations were described in patients with inherited

181 lled eligible patients treated with the same DESs.

182 erwent nonrandomized treatment with the same DESs.

183 itions inducing dermal-epidermal separation (DES).

184 raction (DLLME) using deep eutectic solvent (DES) as the extracting solvent has been developed and ap

185 d ionic liquids (ILs)/deep eutectic solvent (DES) as the transport facilitator.

186 A natural deep eutectic solvent (DES) based on glucose and lactic acid was considered as

187 ovative and practical deep eutectic solvent (DES) based vortex assisted microextraction (DES-VAME) me

188 Deep eutectic solvent (DES) formed by mixing of choline chloride and phenol was

189 sive, simple and fast deep eutectic solvent (DES)-based dispersive liquid-liquid microextraction was

190 ognizing gliadin in a deep eutectic solvent (DES).

191 Deep eutectic solvents (DES) and aqueous glycerol were proposed as green alterna

192 rape skin phenolics, deep eutectic solvents (DES) as a green alternative to conventional solvents cou

193 Deep eutectic solvents (DESs) are "green" solvents, applied in this study for th

194 Deep eutectic solvents (DESs) are an emerging class of mixtures characterized by

195 green, biorenewable deep eutectic solvents (DESs) at room temperature and in the presence of air, es

196 pramolecular gels in deep eutectic solvents (DESs) based on choline chloride combined with alcohols/u

197 Deep eutectic solvents (DESs) have been considered "the organic reaction medium

198 The utilization of deep eutectic solvents (DESs) in electrochemical studies has grown in recent yea

199 Here, two deep eutectic solvents (DESs) used in the agro-food field were studied: xylitol:

200 vents, also known as deep eutectic solvents (DESs).

201 icated by exploiting Deep Eutectic Solvents (DESs).

202 ced foam cell formation compared to standard DES in atherosclerotic rabbits.

203 b BVS or Xience metallic drug-eluting stent (DES) implantation (Abbott Vascular, Santa Clara, Califor

204 eatment of patients with drug-eluting stent (DES) in-stent restenosis (ISR) is more challenging than

205 necessity of polymers on drug-eluting stent (DES) platforms is dictated by the need of an adequate am

206 mparison of contemporary drug-eluting stent (DES) platforms, previous generation DES, and bare-metal

207 olution and iteration of drug-eluting stent (DES) technology, the prevalence of in-stent restenosis (

208 ld (BVS) versus drug-eluting metallic stent (DES) in the same individual receiving multilesion percut

209 rst-generation drug-eluting coronary stents (DES) were introduced in 2003 to 2004, and their use resu

210 Randomized trials of drug-eluting stents (DES) and drug-coated balloons (DCB) for femoropopliteal

211 ted balloons (DCBs) and drug-eluting stents (DES) are available.

212 ) after implantation of drug-eluting stents (DES) are incompletely understood.

213 ) and second-generation drug-eluting stents (DES) at 5 institutions.

214 New-generation drug-eluting stents (DES) have mostly been investigated in head-to-head non-i

215 erventional cardiology, drug-eluting stents (DES) have shown better patency rates and are standard pr

216 ry disease treated with drug-eluting stents (DES) in randomized clinical trials are scant.

217 Implantation of drug-eluting stents (DES) is the dominant treatment strategy for patients wit

218 ary intervention (PCI), drug-eluting stents (DES) reduce repeat revascularizations compared with bare

219 ion of newer-generation drug-eluting stents (DES) remains uncertain.

220 Drug-eluting stents (DES) showed improved efficacy and safety compared with b

221 intervention (PCI) with drug-eluting stents (DES) versus bare metal stents (BMS) has not been studied

222 ons similar to metallic drug-eluting stents (DES), followed by complete bioresorption in approximatel

223 intervention (PCI) with drug-eluting stents (DES), improvements driven mainly by differences in myoca

224 -metal stents (BMS) and drug-eluting stents (DES).

225 raft (SVG) lesions with drug-eluting stents (DES; paclitaxel- or everolimus-eluting stents) for reduc

226 -used, newer-generation drug-eluting stents (DESs) in a broad patient population is of interest.

227 Within patients treated with bigger stents, DES implantation was associated to a trend toward a redu

228 imitations of direct electrical stimulation (DES) of microcircuits, this opens exciting possibilities

229 n was remarkably more soluble in the studied DESs than in pure water.

230 The water incorporated in the supramolecular DES complex stabilizes the transition states and favors

231 significantly different in the 2 groups (SVG-DES: 15.0%, SVG-MT: 20.0%; hazard ratio, 0.65; 95% confi

232 re randomized (1:1) to DES implantation (SVG-DES) or medical treatment (SVG-MT) of the target SVG les

233 n MACE related to the target SVG lesion (SVG-DES: 10.0%, SVG-MT: 16.9%; hazard ratio, 0.53; 95% confi

234 rval, 0.20-1.43; P=0.21) or global MACE (SVG-DES: 36.7%, SVG-MT: 44.6%; hazard ratio, 0.73; 95% confi

235 ty and 65 patients were allocated to the SVG-DES and SVG-MT groups, respectively.

236 espread ocular pathologies-dry eye syndrome (DES) and MG dysfunction (MGD).

237 iseases (12 patients each: dry eye syndrome [DES], contact lens wear, post-laser refractive surgery,

238 t implantation with a strategy of systematic DES implantation in patients at high risk for FP resteno

239 The systematic DES strategy yielded larger post-procedural minimal lumi

240 Our results suggest that DES offers an efficient, safe, sustainable, and cost eff

241 The DES-p.Glu401Asp mutation causes predominant inherited le

242 Evidence for and against the DES+ model is discussed, and experiments are proposed to

243 his segregation becomes unfavorable, and the DES structure is disrupted; instead, water-water and DES

244 in explanted cardiac tissue affected by the DES mutation.

245 Next-generation sequencing confirmed the DES variant c.1216C>T (p.R406W) as the sole disease-caus

246 subgroups of cornea patients, excluding the DES group, for which reproducibility was significantly l

247 Of the 66 family members screened for the DES-p.Glu401Asp mutation, 23 of them were positive, 6 we

248 However, the DES nanostructure is retained to a remarkably high level

249 to VLST presentation was 51.4 months in the DES and 69.9 months in the BMS group (P=0.011).

250 nsor for the quantification of gluten in the DES ethaline.

251 major amputation rate remained lower in the DES group until 2 years post-treatment, with a trend tow

252 patients, 96 in the DCB group and 96 in the DES group, with 240 lesions in 225 limbs, were included.

253 ion (8 versus 2%, P=0.03) were higher in the DES-ISR group.

254 us 2.38+/-0.5 mm, P=0.01) was smaller in the DES-ISR group.

255 At and above this hydration level, the DES-water mixture is best described as an aqueous soluti

256 The yields of the DES extractions were compared with those from convention

257 iteal interventions; a trend in favor of the DES was observed up to 36 months.

258 ts are proposed to address key tenets of the DES+ model.

259 d the substrates, the effect of water on the DES supramolecular network and its physicochemical prope

260 even at low hydration levels, reporting the DES water content is important.

261 differential scanning calorimetry showed the DES nature of the liquid-like phase was retained.

262 Therefore the DES could provide a promising and viable approach for a

263 icantly greater with the BVS compared to the DES (6.7 +/- 12.6% vs. 2.9 +/- 11.5%; p = 0.003); the re

264 and cultured from 2 family members with the DES mutation (1 with mild and 1 with severe symptomatolo

265 ics properties, the interactions between the DESs and the substrates, the effect of water on the DES

266 Finally, the solubility of quercetin in the DESs was higher than in water, especially for GCH.

267 PhAA/TMG DES achieved higher recovery and enrichment factor compa

268 Patients were randomized (1:1) to DES implantation (SVG-DES) or medical treatment (SVG-MT)

269 decreased vascular permeability relative to DES, which was further confirmed by SEM and TEM.

270 DCB was not superior to DES in the treatment of complex FP lesions in a high-ris

271 At 5-year follow-up, CABG was superior to DES-PCI on several SAQ domains including angina frequenc

272 dergoing HLA-incompatible kidney transplant, DES therapy and frequent monitoring for dnDSAs appears c

273 In this work, two DESs have been characterized: d-glucose:choline chloride

274 d 2012, a total of 22,590 patients underwent DES-PCI in western Denmark.

275 gels were similar to those of the unmodified DESs, thus proving the deep eutectic nature of the ionic

276 ounds have been extracted from VOO oil using DES.

277 tection power was improved by 48 times using DES-LPME-SQT-FAAS method with respect to conventional FA

278 ive liquid-liquid microextraction method (VA-DES-DLME) was developed based on hydrophobic deep eutect

279 ed deep eutectic solvent microextraction (VA-DES-ME) procedure has been developed for the preconcentr

280 Consequently, the VA-DES-ME procedure was successfully applied for the extrac

281 worse treatment failure for PTA+/-BMS versus DES (P=0.041).

282 umen loss in lesions treated with BVS versus DES (0.30+/-0.59 versus 0.22+/-0.48 mm; P=0.035).

283 ing framework may be used to predict in vivo DES performance, opening up the possibility of an in sil

284 and no rejection control groups (P < 0.01 vs DES control, P < 0.05 vs non-DES control).

285 omized trial was conducted to assess whether DES also improve patency and clinical outcome of infrapo

286 o evaluate the surgical risk associated with DES-PCI compared with that in nonstented patients withou

287 le intraindividual performance compared with DES.

288 longitudinal extension in BMS compared with DES.

289 saw a time-dependent treatment effect, with DES being associated with lower risk of the primary outc

290 All-cause death was unaffected (HR with DES 0.96, 95% CI 0.88-1.05, p=0.358), but risk was lower

291 ring percutaneous coronary intervention with DES and with BMS in dialysis patients.

292 intermediate nonobstructive SVG lesions with DES was safe but was not associated with a significant r

293 f EES are less satisfactory in patients with DES-ISR than in those with bare-metal stent ISR.

294 teristics were more adverse in patients with DES-ISR, although they presented later and more frequent

295 ained significantly smaller in patients with DES-ISR.

296 /-17%, P<0.001) were poorer in patients with DES-ISR.

297 ischemic and bleeding events after PCI with DES, thereby facilitating clinical decisions surrounding

298 y-four limbs (73 patients) were treated with DES and 66 limbs (64 patients) received PTA+/-BMS.

299 elationship between dose and efficacy within DES.

300 However, at 3 years, DES was associated with 20% (95% confidence interval [CI